1. Chemotherapy vs Immunotherapy in Advanced NSCLC Without Actionable Mutations

2. This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Introduction

4. First-Line Therapy Selection

5. Chemotherapy Options

6. A Case Example of Second-Line Decisions After Chemotherapy

7. Second-Line Immunotherapy vs Docetaxel

8. A Case Example of Second-Line Decisions After Immunotherapy

9. Insights on Sequencing

10. A Case Example of Front-Line Decisions

11. Keynote 024: First-Line Pembrolizumab

12. Keynote 021 Cohort G: First-Line Pembrolizumab + Chemotherapy

13. PD-L1 Subset Data From Keynote 021 Cohort G

14. Keep Considering Chemotherapy

15. Unanswered Questions

16. Concluding Remarks

17. Abbreviations